Sanofi reported Thursday an agreement potentially worth more than $800 million to develop Principia Biopharma's experimental oral treatment PRN2246 for multiple sclerosis, as well as other central nervous system diseases. Under the agreement for the BTK inhibitor, Sanofi will pay Principia $40 million upfront, with the latter eligible to receive milestone payments of up to $765 million, as well as royalties on product sales.
Meanwhile, Principia will receive an option to jointly fund Phase III development in exchange for either increased royalties on global product sales or a profit and loss sharing arrangement in the US. PRN2246, which is currently in Phase I development, is designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling.
FirstWord reports in this therapy area - KOL Insight Multiple Sclerosis: Find out how KOLs expect the market to evolve, which pipeline treatments are most promising, and which clinical trials will shape treatment decisions. Learn more.
Rita Balice-Gordon, global head of Sanofi's multiple sclerosis/neuroscience therapeutic research area, remarked "our agreement with Principia is an example of Sanofi's strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases." Sanofi currently markets the multiple sclerosis treatments Aubagio (teriflunomide) and Lemtrada (alemtuzumab).
To read more Top Story articles, click here.